RnR Market Research

China Megestrol Market 2010-2019 Investigation Report


Dallas, TX -- (SBWIRE) -- 06/22/2015 -- RnRMarketResearch.com adds "Investigation Report on China Megestrol Market, 2010-2019"to its store.

Nowadays, breast cancer has the highest incidence among malignancy for women all over the world. According to the statistics released by World Health Organization (WHO), the number of breast cancer cases around the world reaches 1.2 million per year while a global death toll is about 0.5 million per year. In the past decade, the annual growth rate of the incidence of breast cancer hit 8%. By 2020, the incidence of cancer will increase by 50% and the number of new cases of cancer around the world will reach 15 million per year.

In recent years, the growth rate of the incidence of breast cancer in China ranks first in the world with one in ten women suffering from breast cancer. In 2015, the number of new cases of breast cancer in China has surpassed that of the US and become the largest in the world. In 2014, the number of newly confirmed cases of breast cancer was 0.225 million, increasing sharply by 50% compared with 2004. At the same time, nearly two thirds of newly confirmed cases can survive for more than 20 years with a longterm survival rate rising sharply by 20%. According to WTO, this astonishing progress benefits from the discovery and sale of new drugs with better efficacy and fewer adverse reactions.

Complete report is available @ http://www.rnrmarketresearch.com/investigation-report-on-china-megestrol-market-2010-2019-market-report.html

About two thirds of breast cancer patients use hormone therapy. Common varieties of progestin are medroxyprogesterone and megestrol which act by blocking the source of human estrogen with an unsatisfactory efficacy rate of 30%50%. Since their efficacy is not better than other drugs for breast cancer and their price is relatively high, their sales is not very big. But according to the latest domestic reports, progestin occupies nearly 2% of clinical medication for breast cancer with rising sales. After entering Chinese market, Megestrol develops very fast. Although its sales in 2011 underwent a small decline, it still enjoys an obvious growth trend in recent years. The annual sales of megestrol rose from CNY 29.95 million in 2010 to CNY 37.22 million in 2014 with a compound growth rate of 5.58%.

Readers can get at least the following information through this report:

-market size of megestrol in China
-major manufacturers of megestrol for Chinese market and their market share
-retail price of megestrol in Chinese market
-market outlook of megestrol in China

The author suggests the following groups of people purchase this report:

-manufacturers of progestin
-investors/ research institutions interested in Chinese medicine market
-any interest in medicine market in China, please contact CRI for customized survey service

Purchase a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=387466

Table of Contents

1 Related Concepts of Megestrol
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Megestrol in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Megestrol in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions